Eylea approved in EU for visual impairment due to macular edema secondary to CRVO

The European Commission has approved Eylea (aflibercept, Regeneron Pharmaceuticals Inc.) for the treatment of visual impairment from macular edema secondary to central retinal vein occlusion, Regeneron announced."We are pleased with the approval of Eylea in the E.U. in a second indication," George D. Yancopoulos, MD, PhD, chief scientific officer of Regeneron and president of Regeneron Laboratories, said in a news release from Regeneron. “Our phase 3 studies showed that Eylea improved visual outcomes significantly in macular edema following CRVO.  This additional approval of Eylea is great news for patients in Europe (Read more...)

Full Story →